Revance Therapeutics (NASDAQ:RVNC) reported quarterly sales of $28.40 million which missed the analyst consensus estimate of $28.45 million by 0.18 percent. This is a 51.03 percent increase over sales of $18.80 million the same period last year.
Warren Buffett’s Berkshire Trims Stake In BYD EV Company To Below 15%
Berkshire Hathaway sold 1.33 million Hong Kong-listed shares of electric vehicle maker BYD Co, Ltd (OTC: BYDDF) (OTC: BYDDY) for HK$267.69 million ($34.43 million).
